The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 19, 2023

Filed:

Sep. 09, 2020
Applicant:

Nour Heart, Inc., Vienna, VA (US);

Inventor:

Salwa A. Elgebaly, Vienna, VA (US);

Assignee:

NOUR HEART, INC., Vienna, VA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); G01N 33/68 (2006.01); C12Q 1/6883 (2018.01); C12N 15/113 (2010.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); C12N 15/113 (2013.01); C12Q 1/6883 (2013.01); C12N 15/111 (2013.01); C12N 2310/141 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01); G01N 2800/324 (2013.01); G01N 2800/325 (2013.01); G01N 2800/60 (2013.01);
Abstract

The present invention provides a method for the early diagnosis, prognosis and differentiation of ischemic cardiac events in myocardial ischemia by a Nourin gene-based RNA molecular network of biomarkers to: (a) diagnose unstable angina and AMI (STEMI and NSTEMI) patients, and differentiate between unstable angina and AMI; (b) diagnose ACS patients and differentiate them from symptomatic non-cardiac patients and healthy subjects; (c) diagnose angina in suspected patients with history of chest pain and differentiate angina patients from symptomatic non-angina and healthy subjects; and (d) diagnose 'new-onset' heart failure and provide a prognostic value and risk prediction of progression and deterioration, as well as monitoring patients' response to treatments. Downregulation of Nourin-related lncR-CTB9H12.4 in ischemic heart disease patients compared to symptomatic non-cardiac and healthy subjects, is significantly associated with upregulation of hsa-miR-137 and hsa-miR-106b, and overexpression of mRNA-FTHL-17 and mRNA-ANAPC11, respectively, that results in upregulation of Nourin gene and protein network.


Find Patent Forward Citations

Loading…